In human PBMCs from healthy donors, VTX-2337 stimulated IFNγ, TNFα and IL-1β secretion after 24 h exposure at 0.1–2 μM. These are cellular treatment concentrations, not EC50 values. [2]
Pretreating human PBMCs with VTX-2337 enhanced cetuximab-mediated lysis of UM-22B cancer cells. In the same study, pretreating purified NK cells at 250 nM did not significantly enhance lysis. NK depletion and CD16 blockade supported an NK-dependent, antibody-dependent effect under the tested conditions. [3]
NLRP3-dependent cytokine release in THP-1 cells
Cell-based study · Wild-type THP-1 versus NLRP3-defective THP-1 cells; TPA-differentiated cultures [1]
VTX-2337 induced concentration-related IL-1β and IL-18 release in wild-type cells; the response was absent in NLRP3-defective cells. This supports a cellular NLRP3 requirement, rather than demonstrating direct binding to NLRP3 or receptor selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.03–25 μM, as specified for Fig 2E–F
- Exposure duration
- Overnight
- Method
- VTX-2337 stimulation of wild-type and NLRP3-defective THP-1 cultures
- Reported limits
- Vehicle and salt/form not specified. Shared methods give 3 nM–10 μM for the general IL-1β assay; the adopted E–F range is explicitly supplied in the figure caption.
Methods and source locations
Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337
Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.
Fig 2E–F and caption; Results, NLRP3 inflammasome activation; Methods, Analysis of IL-1β secretion and caspase-1 activation in THP-1 cells; Reagents
Secreted IL-1β and IL-18: ELISA; plotted mean ± SEM from triplicate wells; representative of three independent experiments — Fig 2E–F, image/caption and corresponding Results
Cytokine secretion by human PBMCs
Cell-based study · PBMCs isolated from healthy donor blood [2]
VTX-2337 stimulated IFNγ, TNFα and IL-1β secretion after 24 h. Concentrations are treatment exposures; no potency estimate is derived.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1–2 μM; 0 μM comparison
- Exposure duration
- 24 h
- Method
- Exposure of isolated human PBMCs to VTX-2337
- Reported limits
- Vehicle, salt/form and donor/independent-experiment count for panels A–C are not specified in the read methods/caption; n=3 is explicitly attached to G–I and is not transferred here.
Methods and source locations
Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337
Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.
Fig 3A–C and caption; Results, VTX-2337 induces immune cell activation; Methods, In vitro immune cell activation; Cell lines and reagents
IFNγ, TNFα and IL-1β in culture medium: ELISA; no exact curve values inferred — Fig 3A–C, image/caption and corresponding Results
PBMC-dependent enhancement of cetuximab-mediated cytotoxicity
Cell-based study · Human PBMCs and purified NK cells tested against UM-22B head-and-neck cancer targets [3]
PBMC pretreatment enhanced cetuximab-mediated lysis. Pretreatment of purified NK cells did not significantly enhance lysis under these conditions (reported p=0.13). NK depletion after PBMC pretreatment abolished cytotoxicity, while post-treatment-isolated NK cells retained activity. CD16 blockade abolished NK-cell ADCC.
Literature-Reported Treatment Conditions
- Treatment concentration
- VTX-2337 250 nM; cetuximab or control IgG1 10 μg/mL
- Exposure duration
- 18 h pretreatment, then 4 h cytotoxicity assay
- Method
- Effector pretreatment followed by 51Cr-release assay; PBMC E:T 50:1, purified NK E:T 10:1 (panel b), post-treatment-isolated NK E:T 2.5:1 (panel c)
- Vehicle
- Medium control; compound solvent not specified
- Co-treatment
- Cetuximab; matched IgG1 controls; CD16-blocking 3G8 and NK-depleted effector controls
- Reported limits
- Salt/form and the independent donor count for panels 1a–c are not explicitly stated in the read caption. Patient panel 1d and the 40-donor genotype design are not adopted.
Methods and source locations
Compound reported in the paper: VTX-2337; Compound label in the paper: VTX-2337
Research findings for the named VTX-2337 material in the stated models; no lot validation or salt equivalence.
Fig 1a–c, image/caption; Results, VTX-2337 enhances cetuximab-mediated cellular cytotoxicity; Methods, Cellular components, Cytotoxicity assays and Statistical analysis
Specific target-cell lysis: 51Cr release; spontaneous and maximum-release controls defined in Methods — Fig 1a–c, image/caption; Results paragraphs on purified and depleted NK cells